Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.65 |
| ▸ | CES1 | P23141 | 4/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.62 |
| ▸ | PPARG | P37231 | 7/20 | 0.62 |
| ▸ | PPARD | Q03181 | 7/20 | 0.62 |
| ▸ | PPARA | Q07869 | 7/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TLR2 | O60603 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | FABP4 | P15090 | 2/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Nonanone SCHEMBL4485770 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| 2-Tridecanone SCHEMBL119126 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| 2-Tridecanone SCHEMBL19838551 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL24005728 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL6894926 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| 2-Dodecanone SCHEMBL23501396 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL43776 | 1.00 | — | — | |
| SCHEMBL7618683 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL21044722 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD | |
| SCHEMBL11144661 | 1.00 | CES2 (0.65) | CES2CES1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| WO-2016012333-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| WO-2003018548-A2 | HALOGENATED CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES, AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020115566-A1 | Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-08-22 | — | — | US | disclosed |
| EP-1094798-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | Endorecherche Inc. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-1999046279-A2 | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | ENDORECHERCHE, INC. (CA) | 1999-09-16 | — | — | WO | disclosed |
| EP-0482084-B1 | (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES | UPJOHN CO (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5491236-A | NERVOUS SYTEM DISORDERS | THE UPJOHN COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1991000856-A2 | (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064681-A1 | Therapeutic agent for treating glaucoma | PDE6G, PDE3A, PDE5A | CES2 3683/4885CES1 3854/4885GPR84 295/4885 |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | ZC3HAV1, SLC10A1, CYP51A1 | CES2 614/4885CES1 44/4885GPR84 2733/4885 |
| US-20020115566-A1 | Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof | CALD1, CALU, CLASP1 | CES2 2477/4885CES1 3374/4885GPR84 1633/4885 |
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | CES2 482/4885CES1 92/4885GPR84 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.